A live-attenuated influenza vaccine for H3N2 canine influenza virus.
Canine influenza is a contagious respiratory disease in dogs caused by two subtypes (H3N2 and H3N8) of canine influenza virus (CIV). Currently, only inactivated influenza vaccines (IIVs) are available for the prevention of CIVs. Historically, live-attenuated influenza vaccines (LAIVs) have been shown to produce better immunogenicity and protection efficacy than IIVs. Here, we have engineered a CIV H3N2 LAIV by using the internal genes of a previously described CIV H3N8 LAIV as a master donor virus (MDV) and the surface HA and NA genes of a circulating CIV H3N2 strain. Our findings show that CIV H3N2 LAIV replicates efficiently at low temperature but its replication is impaired at higher temperatures. The CIV H3N2 LAIV was attenuated in vivo but induced better protection efficacy in mice against challenge with wild-type CIV H3N2 than a commercial CIV H3N2 IIV. This is the first description of a LAIV for the prevention of CIV H3N2 in dogs.
Department of Microbiology and Immunology, University of Rochester, Rochester, NY, US.
Laura
L
Rodriguez
Department of Microbiology and Immunology, University of Rochester, Rochester, NY, US.
Aitor
A
Nogales
Department of Microbiology and Immunology, University of Rochester, Rochester, NY, US; David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY, US.
Emma C
EC
Reilly
Department of Microbiology and Immunology, University of Rochester, Rochester, NY, US; David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY, US.
David J
DJ
Topham
MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
Pablo R
PR
Murcia
Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY, US.
Colin R
CR
Parrish
Department of Microbiology and Immunology, University of Rochester, Rochester, NY, US. Electronic address: luis_martinez@urmc.rochester.edu.
Luis
L
Martinez Sobrido
D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D002460:Cell Line; D004283:Dog Diseases / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D004285:Dogs; D005260:Female; D057809:HEK293 Cells; D006801:Humans; D053122:Influenza A Virus, H3N2 Subtype / Q000254:growth & development / Q000276:immunology*; D053123:Influenza A Virus, H3N8 Subtype / Q000254:growth & development / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D061985:Madin Darby Canine Kidney Cells; D051379:Mice; D008810:Mice, Inbred C57BL; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D014613:Vaccines, Attenuated / Q000276:immunology*; D014779:Virus Replication / Q000276:immunology
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated
Attenuated (att); Canine influenza virus (CIV); Cold adapted (ca); Inactivated influenza vaccine (IIV); Influenza A virus (IAV); Live-attenuated influenza vaccine (LAIV); Master donor virus (MDV); Reverse genetics techniques; Temperature sensitive (ts)